INTRODUCTION: Information regarding any possible additional effect of genetic variants other than CYP2C19*2 on platelet reactivity in patients undergoing percutaneous coronary intervention (PCI), while on dual antiplatelet therapy, is sparse. MATERIALS AND METHODS: Genotyping for CYP2C19*2, CYP2C19*17, CYP2C9*3, CYP2B6*5, ABCB1 and P2RY12 (c.-217+2739T>C) variants was performed in 146 consecutive PCI patients receiving clopidogrel. Platelet reactivity was assessed by the Verify Now P2Y12 point-of-care assay and high on-treatment platelet reactivity (HTPR) was defined as a Platelet Reactivity Unit (PRU)≥235. RESULTS: We identified 65(44.5%) patients with HTPR and 38(26%) carriers of at least one CYP2C19*2 allele, which had higher platelet reactivity compared to non-carriers [least square (LS) mean difference 44.5, 95%CI 15.8-77.3, p=0.003]. In the entire study population, the presence of at least one CYP2C19*2 or P2RY12 allelic variant was independently associated with HTPR (OR=3.02, 95%CI 1.16-7.86, p=0.023 and OR=3.11, 95%CI 1.03-9.39, p=0.05 respectively). In CYP2C19*2 non-carriers, carriers of at least one CYP2B6*5 allelic variant had higher platelet reactivity compared to the remainders (LS mean difference 35.6, 95%CI 3.7-67.6, p=0.03) and the presence of at least one CYP2B6*5 or P2RY12 allelic variant was independently associated with HTPR (OR=3.26, 95%CI 1.08-9.86, p=0.04 and OR=4.27, 95%CI 1.11-16.4, p=0.04 respectively). CONCLUSIONS: Apart from the CYP2C19*2, other genetic variants involved in clopidogrel metabolism and action like CYP2B6*5 and P2RY12 seem to have an important association with HTPR.
INTRODUCTION: Information regarding any possible additional effect of genetic variants other than CYP2C19*2 on platelet reactivity in patients undergoing percutaneous coronary intervention (PCI), while on dual antiplatelet therapy, is sparse. MATERIALS AND METHODS: Genotyping for CYP2C19*2, CYP2C19*17, CYP2C9*3, CYP2B6*5, ABCB1 and P2RY12 (c.-217+2739T>C) variants was performed in 146 consecutive PCI patients receiving clopidogrel. Platelet reactivity was assessed by the Verify Now P2Y12 point-of-care assay and high on-treatment platelet reactivity (HTPR) was defined as a Platelet Reactivity Unit (PRU)≥235. RESULTS: We identified 65(44.5%) patients with HTPR and 38(26%) carriers of at least one CYP2C19*2 allele, which had higher platelet reactivity compared to non-carriers [least square (LS) mean difference 44.5, 95%CI 15.8-77.3, p=0.003]. In the entire study population, the presence of at least one CYP2C19*2 or P2RY12 allelic variant was independently associated with HTPR (OR=3.02, 95%CI 1.16-7.86, p=0.023 and OR=3.11, 95%CI 1.03-9.39, p=0.05 respectively). In CYP2C19*2 non-carriers, carriers of at least one CYP2B6*5 allelic variant had higher platelet reactivity compared to the remainders (LS mean difference 35.6, 95%CI 3.7-67.6, p=0.03) and the presence of at least one CYP2B6*5 or P2RY12 allelic variant was independently associated with HTPR (OR=3.26, 95%CI 1.08-9.86, p=0.04 and OR=4.27, 95%CI 1.11-16.4, p=0.04 respectively). CONCLUSIONS: Apart from the CYP2C19*2, other genetic variants involved in clopidogrel metabolism and action like CYP2B6*5 and P2RY12 seem to have an important association with HTPR.
Authors: Thomas O Bergmeijer; Jean-Luc Reny; Ruth E Pakyz; Li Gong; Joshua P Lewis; Eun-Young Kim; Daniel Aradi; Israel Fernandez-Cadenas; Richard B Horenstein; Ming Ta Michael Lee; Ryan M Whaley; Joan Montaner; Gian Franco Gensini; John H Cleator; Kiyuk Chang; Lene Holmvang; Willibald Hochholzer; Dan M Roden; Stefan Winter; Russ B Altman; Dimitrios Alexopoulos; Ho-Sook Kim; Jean-Pierre Déry; Meinrad Gawaz; Kevin Bliden; Marco Valgimigli; Rossella Marcucci; Gianluca Campo; Elke Schaeffeler; Nadia P Dridi; Ming-Shien Wen; Jae Gook Shin; Tabassome Simon; Pierre Fontana; Betti Giusti; Tobias Geisler; Michiaki Kubo; Dietmar Trenk; Jolanta M Siller-Matula; Jurriën M Ten Berg; Paul A Gurbel; Jean-Sebastien Hulot; Braxton D Mitchell; Matthias Schwab; Marylyn DeRiggi Ritchie; Teri E Klein; Alan R Shuldiner Journal: Am Heart J Date: 2017-12-17 Impact factor: 4.749
Authors: Sharon Cresci; Jeremiah P Depta; Petra A Lenzini; Allie Y Li; David E Lanfear; Michael A Province; John A Spertus; Richard G Bach Journal: Circ Cardiovasc Genet Date: 2014-04-24
Authors: Gilberto Vargas-Alarcón; Julián Ramírez-Bello; Aurora de la Peña; Beatriz Calderón-Cruz; Marco Antonio Peña-Duque; Marco Antonio Martínez-Ríos; Silvestre Ramírez-Fuentes; Oscar Pérez-Méndez; José Manuel Fragoso Journal: Mol Biol Rep Date: 2014-08-09 Impact factor: 2.316
Authors: Brittney H Davis; Chrisly Dillon; Anping Cai; Lance A Williams Iii; Salpy V Pamboukian; Nita A Limdi Journal: Pharmacogenomics Date: 2019-05 Impact factor: 2.533
Authors: Adam S Fisch; Christina G Perry; Sarah H Stephens; Richard B Horenstein; Alan R Shuldiner Journal: Curr Cardiol Rep Date: 2013-07 Impact factor: 2.931
Authors: Sarah C Preissner; Michael F Hoffmann; Robert Preissner; Mathias Dunkel; Andreas Gewiess; Saskia Preissner Journal: PLoS One Date: 2013-12-10 Impact factor: 3.240
Authors: Joshua P Lewis; Joshua D Backman; Jean-Luc Reny; Thomas O Bergmeijer; Braxton D Mitchell; Marylyn D Ritchie; Jean-Pierre Déry; Ruth E Pakyz; Li Gong; Kathleen Ryan; Eun-Young Kim; Daniel Aradi; Israel Fernandez-Cadenas; Ming Ta Michael Lee; Ryan M Whaley; Joan Montaner; Gian Franco Gensini; John H Cleator; Kiyuk Chang; Lene Holmvang; Willibald Hochholzer; Dan M Roden; Stefan Winter; Russ B Altman; Dimitrios Alexopoulos; Ho-Sook Kim; Meinrad Gawaz; Kevin P Bliden; Marco Valgimigli; Rossella Marcucci; Gianluca Campo; Elke Schaeffeler; Nadia P Dridi; Ming-Shien Wen; Jae Gook Shin; Pierre Fontana; Betti Giusti; Tobias Geisler; Michiaki Kubo; Dietmar Trenk; Jolanta M Siller-Matula; Jurriën M Ten Berg; Paul A Gurbel; Matthias Schwab; Teri E Klein; Alan R Shuldiner Journal: Eur Heart J Cardiovasc Pharmacother Date: 2020-07-01